Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
75.00 USD   -0.70%
11/23Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
BU
11/17Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
BU
11/15Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Sell: Novocure

09/12/2022 | 04:38pm EST


ę MT Newswires 2022
All news about NOVOCURE LIMITED
11/23Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
BU
11/17Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-O..
BU
11/15Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
BU
11/15Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
CI
11/14Novocure Secures CE Mark for New Array
AQ
11/11NovoCure Says it Will Initiate Limited Market Release of Transducer Array in Europe Aft..
MT
11/11Novocure Secures CE Mark for New Array
BU
11/04Novocure Ltd : Other Events (form 8-K)
AQ
10/28Wells Fargo Adjusts Price Target on NovoCure to $74 From $70, Keeps Equal Weight Rating
MT
10/28Truist Securities Trims NovoCure's Price Target to $102 From $105, Maintains Buy Rating
MT
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 538 M - -
Net income 2022 -83,2 M - -
Net Debt 2022 113 M - -
P/E ratio 2022 -92,6x
Yield 2022 -
Capitalization 7 871 M 7 871 M -
EV / Sales 2022 14,8x
EV / Sales 2023 14,3x
Nbr of Employees 1 167
Free-Float 98,9%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 75,00 $
Average target price 89,38 $
Spread / Average Target 19,2%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED-0.11%7 871
SHOCKWAVE MEDICAL, INC.48.19%9 551
MASIMO CORPORATION-50.53%7 614
PENUMBRA, INC.-31.80%7 442
GETINGE AB-41.53%6 033
ASAHI INTECC CO., LTD.5.14%5 069